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Purpose: We aimed to assess the clinical value of endorectal magnetic resonance imag-
ing (MRI) in predicting extraprostatic extension and seminal vesicle invasion in pa-
tients with clinically localized prostate cancer.
Materials and Methods: A total of 54 patients who underwent radical prostatectomy 
for clinically localized prostate cancer were retrospectively analyzed. The findings of 
endorectal MRI, performed at least 3 weeks after biopsy, were compared with the patho-
logical results of radical prostatectomy specimens. The sensitivity, specificity, and ac-
curacy of the detection of extraprostatic extension and seminal vesicle invasion were 
calculated.
Results: The sensitivity, specificity, and accuracy of the endorectal MRI findings were 
50.0%, 82.6%, and 77.8% for the detection of extraprostatic extension, respectively, and 
75.0%, 92.0%, and 90.7% for the detection of seminal vesicle invasion, respectively. The 
sensitivity of endorectal MRI in the detection of extraprostatic extension improved as 
the Gleason score increased. 
Conclusions: Endorectal MRI findings demonstrated modest sensitivity for predicting 
extraprostatic extension, whereas specificity was relatively high. In addition, endor-
ectal MRI showed better sensitivity for detecting high-grade tumors.
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INTRODUCTION
Treatment of prostate cancer is greatly dependent on local 
staging, particularly the presence or absence of extra-
prostatic extension. As a general rule, patients with disease 
localized to the prostate are candidates for radical prosta-
tectomy, whereas those with tumor extension beyond the 
prostatic capsule are probably more appropriately man-
aged with radiation therapy. Hence, we have to find a way 
to perform accurate staging at diagnosis. A variety of imag-
ing modalities have been evaluated for staging prostate 
cancer. However, none of these techniques is sensitive 
enough to reliably detect extraprostatic extension and 
seminal vesicle invasion of prostatic cancer [1,2]. For over 
two decades, magnetic resonance imaging (MRI) has im-
proved our ability to delineate localized versus locally ad-
vanced prostate cancer [3]. Although it seems to have limi-
tations with respect to the diagnosis of microscopic extra-
prostatic cancer [4], MRI using an endorectal coil combined 
with phased-array coils remains the most promising tech-
nique for the detection and staging of prostate cancer [5]. 
　The present study was undertaken to evaluate the ability 
of endorectal coil MRI to predict extraprostatic extension 
and seminal vesicle invasion in patients with clinically lo-
calized prostate cancer. In addition, we investigated the 
changes in sensitivity, specificity, and accuracy when pa-
tients were subdivided into groups according to their Glea-
son scores and serum prostate-specific antigen (PSA) values.
MATERIALS AND METHODS
A total of 54 patients who underwent radical prostatectomy Korean J Urol 2010;51:308-312
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TABLE 1. Clinicopathologic characteristics of patients included 
in the study sample
No. of patients
Age (years) 
Baseline PSA (ng/ml)
Interval between biopsy and MRI (days)
Max tumor diameter on endorectal MRI (cm)
Gleason score
6
7
8 
9
Clinical stage
cT1
cT2
Surgical stage
pT2
pT3a-b
pT3c
54
63.5 (50-72)
a
7.35 (3.5-41.2)
a
37.5 (21-72)
a
2.15 (0.5–4.8)
a
30 (55.6%)
19 (35.2%)
3 (5.6%)
2 (3.7%)
32 (59.3%)
22 (40.7%)
45 (83.3%)
5 (9.3%)
4 (7.4%)
PSA: prostate-specific antigen, MRI: magnetic resonance imag-
ing, 
a: data are presented as the median value with the range in 
parentheses
TABLE 2. Diagnostic performance of endorectal MRI for detecting extraprostatic extension of prostate cancer
No. of patients
No. of cases/total number (%)
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Overall
Gleason score
＜7
7
＞7
PSA
＜10
≥10
Partin table
b
54
30
19
5
37
17
54
4/8 (50)
0/3 (0)
a
2/3 (67)
a
2/2 (100)
a
1/3 (33)
3/5 (60)
5/8 (63)
38/46 (83)
23/27 (85)
13/16 (81)
2/3 (67)
30/34 (88)
8/12 (67)
32/46 (70)
4/12 (33)
0/4 (0)
2/5 (40)
2/3 (67)
1/5 (20)
3/7 (43)
5/19 (26)
38/42 (90)
23/26 (89)
13/14 (93)
2/2 (100)
30/32 (94)
8/10 (80)
32/35 (91)
42/54 (78)
23/30 (77)
15/19 (79)
4/5 (80)
31/37 (84)
11/17 (65)
37/54 (69)
MRI: magnetic resonance imaging, PPV: positive predictive value, NPV: negative predictive value, PSA: prostate-specific antigen, 
a: 
chi-square test: linear by linear association, p=0.034, 
b: data was presumed on the basis of the Partin tables [28]
for clinically localized prostate cancer were retrospectively 
analyzed. By use of the same protocol, endorectal MRI (1.5 
T) was performed before surgery in all patients. Patients 
who received neoadjuvant treatment after the endorectal 
MRI examination and patients who had undergone a prostate 
biopsy and endorectal MRI within 3 weeks of each other 
were excluded from the present study [6,7]. The criteria for 
diagnosis of extraprostatic extension on endorectal MRI in-
cluded the following: a localized bulge of the prostatic con-
tour, a thickening or disruption of the prostatic capsule, an 
infiltrative strand in the periprostatic fat, or asymmetry 
of the neurovascular bundle [8-10]. Seminal vesicle in-
vasion was defined by abnormal tissue with low signal in-
tensity within the seminal vesicle or dilatation of the semi-
nal vesicle with asymmetry [8-10]. Radiologic inter-
pretations were made by the consensus of two radiologists. 
The endorectal MRI findings were compared with the histo-
pathologic findings of the radical prostatectomy specimen 
in each patient.
1. Protocol for endorectal MRI
The endorectal coil was inserted and the patient was posi-
tioned supine between the phased-array coils. All patients 
underwent MRI with a superconducting MRI scanner op-
erating at 1.5 Tesla (Signa Horizon LX, GE Yokogawa 
Medical Systems, Hino, Japan). Axial T2-weighted fast 
spin echo (TR/TE 3,500 ms/102 ms, 16 echo train lengths, 
256x192 matrix, 4-mm slice thickness, 0.5-mm interslice 
gap, number of excitations: 4), T1-weighted spin echo 
(TR/TE 400 ms/9 ms), and coronal T2-weighted fast spin 
echo (TR/TE 3,200 ms/92 ms) images were obtained. After 
precontrast image acquisition, 0.1 mmol/kg of gadopente-
tate dimeglumine was administered intravenously and ax-
ial T1-weighted spin echo images with the same imaging 
parameters or axial T1-weighted fast spoiled gradient re-
called acquisition in steady state (GRASS) with fat sup-
pression (TR/TE/flip angle 200 ms/3.1 ms/90
o) images were 
obtained. The field of view was 14x14 cm. A four-channel 
phased-array coil was used that consisted of four surface 
coils (Pelvic Array, GE Yokogawa Medical Systems, Hino, 
Japan) and one endorectal coil (MRInnervu BPX-15, Nihon 
Medrad KK, Osaka, Japan) that were used together. One 
channel of the phased-array coil was replaced with an en-
dorectal coil so that the detection system could encompass 
the entire pelvis and prostate.
2. Statistical analysis
Because the number of positive cases was low, we per-
formed the chi-square trend test instead of the traditional 
chi-square test to determine a statistically significant line-
ar trend in sensitivity for detecting extraprostatic ex-
tension based on the Gleason score. Differences were con-
sidered statistically significant at p＜0.05.
RESULTS
Clinicopathologic parameters are summarized in Table 1. Korean J Urol 2010;51:308-312
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TABLE 3. Diagnostic performance of endorectal MRI for detecting seminal vesicle invasion of prostate cancer
No. of patients
No. of cases/total number (%)
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Overall
Gleason score
＜7
7
＞7
PSA
＜10
≥10
54
 
30
19
5
 
37
17
3/4 (75)
 
0/1 (0)
2/2 (100)
1/1 (100)
 
1/2 (50)
2/2 (100)
46/50 (92)
 
26/29 (90)
16/17 (94)
4/4 (100)
 
32/35 (91)
14/15 (93)
3/7 (43)
 
0/3 (0)
2/3 (67)
1/1 (100)
 
1/4 (25)
2/3 (67)
46/47 (98)
 
26/27 (96)
16/16 (100)
4/4 (100)
 
32/33 (97)
14/14 (100)
49/54 (91)
 
26/30 (87)
18/19 (95)
5/5 (100)
 
33/37 (89)
16/17 (94)
MRI: magnetic resonance imaging, PPV: positive predictive value, NPV: negative predictive value, PSA: prostate-specific antigen
Surgical-pathologic analysis revealed eight (14.8%) pa-
tients with extraprostatic extension, including four (7.4%) 
patients with seminal vesicle invasion. Endorectal MRI 
demonstrated suspected extraprostatic extension in 12 pa-
tients and suspected seminal vesicle invasion in 7 patients. 
The sensitivity, specificity, and accuracy of endorectal MRI 
for the detection of extraprostatic extension were 50.0%, 
82.6%, and 77.8%, respectively, and the sensitivity, specif-
icity, and accuracy for the detection of seminal vesicle in-
vasion were 75.0%, 92.0%, and 90.7%, respectively (Table 
2, 3). The sensitivity of endorectal MRI for the detection of 
extraprostatic extension and seminal vesicle invasion 
tended to increase as the Gleason score or PSA increased. 
In particular, chi-square trend analysis showed a signi-
ficant linear trend in groups with different Gleason scores 
(p=0.034). When the Gleason score was 8 or greater, endor-
ectal MRI predicted seminal vesicle invasion perfectly.
DISCUSSION
The typical presentation of prostate cancer has changed 
greatly over the past two decades. Currently, more men are 
presenting with well-differentiated tumors, low PSA lev-
els, and nonpalpable disease. This dramatic shift in pre-
sentation, which may be due to PSA use, has caused a major 
stage migration for prostate cancer, with nearly 80% of 
newly diagnosed cases revealing only localized disease 
[11,12]. In patients with localized prostate cancer, radical 
prostatectomy is the most effective treatment tool and of-
fers the best chance of a cure [13]. However, over 30% of men 
with clinically localized prostate cancer are found to have 
extraprostatic extension by surgical pathologic analysis 
[14,15]. Moreover, many of the long-term complications of 
radical prostatectomy, such as urinary incontinence and 
impotence, have a large impact on patients' quality of life 
and, in some patients, may offset the clinical benefits [16]. 
Therefore, accurate cancer staging at diagnosis is crucial. 
　The use of computed tomography and MRI to evaluate 
the local extent of disease is not routinely recommended be-
cause of the low sensitivity and accompanying low cost-ef-
fectiveness of these modalities [1,10,17]. Nevertheless, 
MRI using an endorectal coil combined with phased-array 
coils remains the most promising technique for the de-
tection and staging of prostate cancer [5].
　The sensitivity of the detection and correct localization 
of peripheral zone disease by use of T2 sequences was re-
ported to vary significantly between 37% and 96% [18]. For 
the detection of extraprostatic extension, the sensitivity, 
specificity, and accuracy of endorectal MRI has been re-
ported to range from 13-71%, 47-97%, and 58-91%, re-
spectively, whereas for the detection of seminal vesicle in-
vasion, the sensitivity, specificity, and accuracy of endor-
ectal MRI has been reported to range from 33-71%, 83-99%, 
and 80-95%, respectively [19-21]. In the present study, the 
sensitivity, specificity, and accuracy for the detection of ex-
traprostatic invasion was 50%, 83%, and 78%, respectively, 
and that for the detection of seminal vesicle invasion was 
75%, 92%, and 91%, respectively. As a result of the inability 
of MRI to visualize microscopic disease, its sensitivity in 
detecting extraprostatic extension is uniformly less than 
75%. However, in clinical practice, a staging tool must have 
a high sensitivity to prevent unnecessary surgeries that 
could negatively impact quality of life. Therefore, it is im-
perative that we develop a method with an appropriately 
high sensitivity. Ellis et al reported that high-grade tumors 
are more likely to be detected on T2 sequences [22]. Later, 
Ikonen et al confirmed that endorectal MRI detects poorly 
differentiated prostate cancer lesions more accurately 
than well-differentiated tumors, although there was no 
statistically significant difference between PSA groups in 
the detection of tumors [4]. In our study, chi-square trend 
analysis also showed a significant linear trend in groups 
with different Gleason scores. This observation seems to 
be the result of greater variation in the tumor's micro-
structure [23]. Therefore, endorectal MRI could be advo-
cated in patients with high Gleason scores. 
　There are several limitations to our study. First, the 
number of enrolled cases was small and just eight (14.8%) 
patients had extraprostatic extension. Therefore, the stat-
istical power is unavoidably weak. Second, we could not 
compare the sensitivity of endorectal MRI for detecting 
seminal vesicle invasion according to Gleason scores be-
cause the number of positive cases was too small. Third, on-
ly prostate cancer in the peripheral zone was assessed in Korean J Urol 2010;51:308-312
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the present study; if prostate cancer in the central gland 
had been included, the overall accuracy and sensitivity 
might have been lower. Finally, the use of MRI in prostate 
cancer is evolving. Recently, several studies have convinc-
ingly shown that dynamic contrast enhancement sequenc-
ing and spectroscopy each improve the detection rate and 
sensitivity of MRI [24,25]. In addition, diffusion-weighted 
imaging of standard T2-weighted sequences and 3T MRI 
may improve cancer identification [26,27]. The use of these 
tools will likely yield even better results.
CONCLUSIONS
Endorectal MRI demonstrated modest sensitivity and a 
relatively high specificity for predicting extraprostatic ex-
tension of clinically localized prostate cancer in a small 
sample of patients. The sensitivity was higher in poorly dif-
ferentiated prostatic cancer than in well-differentiated 
prostate cancer. Using endorectal MRI, we were able to 
more accurately predict seminal vesicle invasion than ex-
traprostatic extension. 
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